Episode details
Available for over a year
The clinical guidelines group NICE has rejected a cancer drug Kadcyla for being too expensive. The drug was trialled here in Bath. Steve le Fevre asked Dr Rav Seeruthun, the medical lead for breast cancer at Roche, who developed the drug, why it is so expensive.
Programme Website